PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Remarkably, many of these patients are highly responsive to checkpoint blockade treatment (Diaz and Le, 2015; Le et al., 2017; Le et al., 2015) where the tumor infiltrating CD8+ cytotoxic T cells can be reactivated by anti-PD1 antagonists to effectively eradicate tumors.”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Diaz and Le, 2015
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Epitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H. L., Wong, S. F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu100 · Cited by 288
Cited by
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417
Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., Teh, B. T., Wongkham, S., & Gores, G. J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00300-2 · Cited by 841
The inflammatory pathogenesis of colorectal cancer
Schmitt, M., & Greten, F. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00534-x · Cited by 775
Comprehensive Analysis of Hypermutation in Human Cancer
Campbell, B. B., Light, N., Fabrizio, D., Zatzman, M., Fuligni, F., de Borja, R., Davidson, S., Edwards, M., Elvin, J. A., Hodel, K. P., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.048 · Cited by 765
“We also note that this coincides with the median mutation burden of patients previously reported to respond to checkpoint inhibition (Bouffet et al., 2016; Diaz and Le, 2015; Johanns et al., 2016; Le et al., 2015; Rizvi et al., 2015; Santin et al., 2016; Snyder et al., 2014; Van Allen et al., 2015).”
Genetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
Baretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 556
Application of PD-1 Blockade in Cancer Immunotherapy
Wu, X., Gu, Z., Chen, Y., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 531
Microsatellite instability: a review of what the oncologist should know
Li, K., Luo, H., Huang, L., Luo, H., & Zhu, X. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1091-8 · Cited by 509
De Velasco, G., Je, Y., Bossé, D., Awad, M. M., Ott, P. A., Moreira, R. B., Schutz, F., Bellmunt, J., Sonpavde, G. P., Hodi, F. S., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0237 · Cited by 486
Zhang, Y., Chandra, V., Riquelme Sanchez, E., Dutta, P., Quesada, P. R., Rakoski, A., Zoltan, M., Arora, N., Baydogan, S., Horne, W., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190354 · Cited by 448
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Zhang, H., Liu, L., Liu, J., Dang, P., Hu, S., Yuan, W., Sun, Z., Liu, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01725-x · Cited by 389
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9807 · Cited by 360
Organoid technology and applications in cancer research
Xu, H., Lyu, X., Yi, M., Zhao, W., Song, Y., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0662-9 · Cited by 345
Xu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y., Tu, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02664 · Cited by 347
Microenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Overacre-Delgoffe, A. E., Bumgarner, H. J., Cillo, A. R., Burr, A. H. P., Tometich, J. T., Bhattacharjee, A., Bruno, T. C., Vignali, D. A. A., & Hand, T. W. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.003 · Cited by 318
The intracellular signalosome of PD-L1 in cancer cells
Escors, D., Gato-Cañas, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 292
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Passarelli, A., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22190 · Cited by 275
High-dose vitamin C enhances cancer immunotherapy
Magrì, A., Germano, G., Lorenzato, A., Lamba, S., Chilà, R., Montone, M., Amodio, V., Ceruti, T., Sassi, F., Arena, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8707 · Cited by 285
He, Y., Yu, H., Rozeboom, L., Rivard, C. J., Ellison, K., Dziadziuszko, R., Suda, K., Ren, S., Wu, C., Hou, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.019 · Cited by 268
Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)
Ahmad, R., Singh, J., Wunnava, A., Al‑Obeed, O., Abdulla, M., & Srivastava, S. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4847 · Cited by 189
Determinants of metastatic competency in colorectal cancer
Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 258
“Notably responsive are hypermutated MSI tumours, which commonly carry many neoantigens, are heavily infiltrated by T lymphocytes and express relatively high levels of various checkpoints (Diaz and Le, 2015; Kloor et al., 2010; Llosa et al., 2015).”
BackgroundWillis, J., Lefterova, M. I., Artyomenko, A., Kasi, P. M., Nakamura, Y., Mody, K., Catenacci, D. V. T., Fakih, M., Barbacioru, C., Zhao, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1324 · Cited by 239
The Immune Biology of Microsatellite-Unstable Cancer
Kloor, M., & von Knebel Doeberitz, M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.02.004 · Cited by 245
The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer
De Palma, F., D’Argenio, V., Pol, J., Kroemer, G., Maiuri, M., & Salvatore, F. (2019) · Cancers · doi:10.3390/cancers11071017 · Cited by 213
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Tian, J., Chen, J. H., Chao, S. X., Pelka, K., Giannakis, M., Hess, J., Burke, K., Jorgji, V., Sindurakar, P., Braverman, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02181-8 · Cited by 198
Wei, F., Zhang, T., Deng, S.-C., Wei, J.-C., Yang, P., Wang, Q., Chen, Z.-P., Li, W.-L., Chen, H.-C., Hu, H., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.022 · Cited by 197
Metabolism‐associated molecular classification of hepatocellular carcinoma
Yang, C., Huang, X., Liu, Z., Qin, W., & Wang, C. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12639 · Cited by 189
“Particularly, it has been demonstrated that neoantigens load and overall mutations load may drive T-cell responses (Diaz and Le, 2015; McGranahan et al., 2016).”
BackgroundLymphocyte‐activation gene‐3, an important immune checkpoint in cancer
He, Y., Rivard, C. J., Rozeboom, L., Yu, H., Ellison, K., Kowalewski, A., Zhou, C., & Hirsch, F. R. (2016) · Cancer Science · doi:10.1111/cas.12986 · Cited by 185
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0554-cp · Cited by 172
Xu, X., Lv, J., Guo, F., Li, J., Jia, Y., Jiang, D., Wang, N., Zhang, C., Kong, L., Liu, Y., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00814 · Cited by 173
Zhai, J., Chen, H., Wong, C. C., Peng, Y., Gou, H., Zhang, J., Pan, Y., Chen, D., Lin, Y., Wang, S., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.04.032 · Cited by 158
Lang, T., Liu, Y., Zheng, Z., Ran, W., Zhai, Y., Yin, Q., Zhang, P., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201806202 · Cited by 165
Correlations between microsatellite instability and the biological behaviour of tumours
Yang, G., Zheng, R.-Y., & Jin, Z.-S. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03053-4 · Cited by 160
Wu, S.-P., Liao, R.-Q., Tu, H., Wang, W., Dong, Z., Huang, S., Guo, W., Gou, L.-Y., Sun, H., Zhang, Q., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.132 · Cited by 163
Immune Checkpoint in Glioblastoma: Promising and Challenging
Huang, J., Liu, F., Liu, Z., Tang, H., Wu, H., Gong, Q.-N., & Chen, J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00242 · Cited by 166
Wang, D., Niu, X., Wang, Z., Song, C.-L., Huang, Z., Chen, K.-N., Duan, J., Bai, H., Xu, J., Zhao, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1086 · Cited by 150
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman‐Vokoun, A. M., Funkhouser, W. K., Kopetz, S., Lieu, C. H., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.11.001 · Cited by 157
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
Zhang, C., Li, Z., Qi, F., Hu, X., & Luo, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.84 · Cited by 165
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S., & Kopetz, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.001 · Cited by 156
Fusobacterium and Colorectal Cancer
Zhou, Z., Chen, J., Yao, H., & Hu, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00371 · Cited by 152
Recent developments in immunotherapy for gastrointestinal tract cancers
Chong, X., Madeti, Y., Cai, J., Li, W., Cong, L., Lu, J., Mo, L., Liu, H., He, S., Yu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01578-x · Cited by 147
Applying artificial intelligence for cancer immunotherapy
Xu, Z., Wang, X., Zeng, S., Ren, X., Yan, Y., & Gong, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.007 · Cited by 126
Li, Z., Song, W., Rubinstein, M., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0684-3 · Cited by 119
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Osorio, J. C., Arbour, K. C., Le, D. T., Durham, J. N., Plodkowski, A. J., Halpenny, D. F., Ginsberg, M. S., Sawan, P., Crompton, J. G., Yu, H. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00709 · Cited by 119
Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma
Landry, A., Balas, M., Alli, S. B., Spears, J., & Zador, Z. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-76657-3 · Cited by 122
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 127
Advances in artificial intelligence to predict cancer immunotherapy efficacy
Xie, J., Luo, X., Deng, X., Tang, Y., Tian, W., Cheng, H., Zhang, J., Zou, Y., Guo, Z., & Xie, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1076883 · Cited by 125
Genetic counseling and cascade genetic testing in Lynch syndrome
Hampel, H. (2016) · Familial Cancer · doi:10.1007/s10689-016-9893-5 · Cited by 113
Ma, R., Yi, B., Riker, A. I., & Xi, Y. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00508-0 · Cited by 113
A machine learning approach for somatic mutation discovery
Wood, D. E., White, J. R., Georgiadis, A., Van Emburgh, B., Parpart-Li, S., Mitchell, J., Anagnostou, V., Niknafs, N., Karchin, R., Papp, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7939 · Cited by 103
Zhao, T., Li, Y., Zhang, J., & Zhang, B. (2020) · Oncology Letters · doi:10.3892/ol.2020.11647 · Cited by 108
Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases
Sun, J., Wang, C., Zhang, Y., Xu, L., Fang, W. J., Zhu, Y., Zheng, Y., Chen, X., Xie, X., Hu, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10987-3 · Cited by 103
Liu, J., Kong, X., Huang, T., Wang, R., Li, W., & Chen, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02048 · Cited by 103
Park, S., Lee, H., Lee, B., Lee, S., Sun, J., Park, W., Ahn, J. S., Ahn, M., & Park, K. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.014 · Cited by 93
Guo, L., Wang, Y., Yang, W., Wang, C., Guo, T., Yang, J., Shao, Z., Cai, G., Cai, S., Zhang, L., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.04.029 · Cited by 93
Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium
Willis, B. C., Sloan, E. A., Atkins, K. A., Stoler, M. H., & Mills, A. M. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.67 · Cited by 86
Wang, Z., Wang, X., Xu, Y., Li, J., Zhang, X., Peng, Z., Hu, Y., Zhao, X., Dong, K., Zhang, B., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02327-y · Cited by 90
Cho, K. R., Cooper, K., Croce, S., Djordevic, B., Herrington, C. S., Howitt, B. E., Hui, P., Ip, P. P. C., Köbel, M., Lax, S., et al. (2018) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000496 · Cited by 84
Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
Shin, M. H., Kim, J., Lim, S. A., Kim, J., & Lee, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072531 · Cited by 87
Lee, K. S., Kwak, Y., Ahn, S., Shin, E. H., Oh, H., Kim, D., Kang, S., Choe, G., Kim, W. H., & Lee, H. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1999-6 · Cited by 84
Direct Detection and Quantification of Neoantigens
Wang, Q., Douglass, J., Hwang, M. S., Hsiue, E. H.-C., Mog, B. J., Zhang, M., Papadopoulos, N., Kinzler, K. W., Zhou, S., & Vogelstein, B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0107 · Cited by 72
Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
Liu, J., Huang, X., Liu, H., Wei, C., Ru, H., Qin, H., Lai, H., Meng, Y., Wu, G., Xie, W., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02638-9 · Cited by 85
“Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) CRC exhibit an active immune microenvironment due to the hyper-mutated state of the tumor cells [23].”
BackgroundRivero, J. D., Cordes, L. M., Kłubo-Gwieździńska, J., Madan, R. A., Nieman, L. K., & Gulley, J. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0470 · Cited by 81
The clinical utility of microsatellite instability in colorectal cancer
Diao, Z., Han, Y., Chen, Y., Zhang, R., & Li, J. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103171 · Cited by 85
Nassar, A. H., Mouw, K. W., Jegede, O. A., Shinagare, A. B., Kim, J., Liu, C., Pomerantz, M. M., Harshman, L. C., Allen, E. M. V., Wei, X. X., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0686-0 · Cited by 78
m6A and m5C modification of GPX4 facilitates anticancer immunity via STING activation
Chen, B., Hong, Y., Zhai, X., Deng, Y., Hu, H., Tian, S., Zhang, Y., Ren, X., Zhao, J., & Jiang, C. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06241-w · Cited by 88
Xu, P., Yang, J. C., Chen, B., Nip, C., Dyke, J. E. V., Zhang, X., Chen, H., Evans, C. P., Murphy, W. J., & Liu, C. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006581 · Cited by 80
Immunotherapy in Gastrointestinal Cancers
Procaccio, L., Schirripa, M., Fassan, M., Vecchione, L., Bergamo, F., Prete, A. A., Intini, R., Manai, C., Dadduzio, V., Boscolo, A., et al. (2017) · BioMed Research International · doi:10.1155/2017/4346576 · Cited by 89
Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
Han, X., Xu, Y., Geranpayehvaghei, M., Anderson, G. J., Li, Y., & Nie, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119745 · Cited by 71
Taylor, K., Yau, H. L., Chakravarthy, A., Wang, B., Shen, S. Y., Ettayebi, I., Ishak, C. A., Bedard, P. L., Razak, A. A., Hansen, A. R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000883 · Cited by 78
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 83
“TGF-β signaling plays a role in immune modulation, and the gene encoding the type II TGF-β receptor is frequently mutated in dMMR colon cancers [56].”
BackgroundMHC class II restricted neoantigen: A promising target in tumor immunotherapy
Sun, Z., Chen, F., Meng, F., Wei, J., & Liu, B. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.039 · Cited by 79
Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel
Yu, Z., Li, X., Duan, J., & Yang, X. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s267177 · Cited by 74
Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
Wang, H., Niu, X., Jin, Z., Zhang, S., Fan, R., Xiao, H., & Hu, S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03519-z · Cited by 94
Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development
Angius, G., Tomao, S., Stati, V., Vici, P., Bianco, V., & Tomao, F. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03950-y · Cited by 73
Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
Wang, D.-K., Zuo, Q., He, Q., & Li, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705999 · Cited by 74
Cui, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01002 · Cited by 77
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
Simeone, E., Grimaldi, A. M., Festino, L., Vanella, V., Palla, M., & Ascierto, P. A. (2017) · BioDrugs · doi:10.1007/s40259-016-0208-z · Cited by 71
Colorectal cancer vaccines: The current scenario and future prospects
Jia, W., Zhang, T., Huang, H., Feng, H., Wang, S., Guo, Z., Luo, Z., Ji, X., Cheng, X., & Zhao, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.942235 · Cited by 62
“The higher mutation frequency of CRC (102) especially for the MSI-H subgroup and the high-frequency and relatively TABLE 3 Major clinical trials of neoantigen vaccines in CRC. NCT Number (status) Tumor Interventions Adjuvant/combined therapy Phases (Enrollment) Completion Date NCT05141721 (Not yet recruiting) mCRC GRT…”
BackgroundInfluentialMolecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman‐Vokoun, A. M., Funkhouser, W. K., Kopetz, S., Lieu, C. H., Lindor, N. M., Minsky, B. D., et al. (2017) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw209 · Cited by 69
Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets
Fonkoua, L. A. K., & Yee, N. S. (2018) · Biomedicines · doi:10.3390/biomedicines6010032 · Cited by 69
Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer
Liu, Y., Qiu, N., Shen, L., Liu, Q., Zhang, J., Cheng, Y., Lee, K., & Huang, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.040 · Cited by 66
Tolba, M. F. (2020) · International Journal of Cancer · doi:10.1002/ijc.33056 · Cited by 73
New developments in systemic therapy for advanced biliary tract cancer
Morizane, C., Ueno, M., Ikeda, M., Okusaka, T., Ishii, H., & Furuse, J. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy082 · Cited by 62
He, Y., Rozeboom, L. M., Rivard, C. J., Ellison, K. E., Dziadziuszko, R., Yu, H., Zhou, C., & Hirsch, F. R. (2017) · Medical Science Monitor · doi:10.12659/msm.899909 · Cited by 65
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 64
A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC
Pan, D., Hu, A. Y., Antonia, S. J., & Li, C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.021 · Cited by 68
Immunotherapy in breast cancer: current landscape and emerging trends
Ran, R., Chen, X., Yang, J., & Xu, B. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00667-y · Cited by 67
Akce, M., Farran, B., Switchenko, J. M., Rupji, M., Kang, S., Khalil, L. E., Ruggieri, A. N., Olson, B. M., Shaib, W. L., Wu, C. S.-Y., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007235 · Cited by 62
Wang, Q., Yu, M., & Zhang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440830 · Cited by 68
Lu, S., Xu, J., Zhao, Z., Guo, Y., Zhang, H., Jurutka, P. W., Huang, D., Cao, C., & Cheng, S. (2023) · Food & Function · doi:10.1039/d3fo02018e · Cited by 59
Kijima, T., Hazama, S., Tsunedomi, R., Tanaka, H., Takenouchi, H., Kanekiyo, S., Inoue, Y., Nakashima, M., Iida, M., Sakamoto, K., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.5267 · Cited by 57
Gao, C., Li, H., Liu, C., Xu, X., Zhuang, J., Zhou, C., Liu, L., Feng, F., & Sun, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650491 · Cited by 61
New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation
Curran, M. A., & Glisson, B. S. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-121900 · Cited by 61
Clinical Implications of Mismatch Repair Deficiency in Prostate Cancer
Sedhom, R., & Antonarakis, E. S. (2019) · Future Oncology · doi:10.2217/fon-2019-0068 · Cited by 60
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Rahman, M. M., Behl, T., Islam, M. R., Alam, M. N. A., Islam, M. M., Albarrati, A., Albratty, M., Meraya, A. M., & BUNGAU, S. G. (2022) · Molecules · doi:10.3390/molecules27123798 · Cited by 57
“Progressive metastatic colorectal cancer 10 mg/kg/every 2 weeks n/a 40/0 [67]”
Background
Metadata
- Authors
- Asaoka, Y., Ijichi, H., & Koike, K.
- ORCID
- Hideaki Ijichi
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-12
- Volume
- 373
- Issue
- 20
- Pages
- 1979-1979
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2597802455
- Cited by
- 426
- References
- 3
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 31 · 2023: 52 · 2022: 46 · 2021: 52 · 2020: 60 · 2019: 45 · 2018: 24 · 2017: 30 · 2016: 18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- anti-PD-1 therapy, mismatch repair deficiency, cancer immunotherapy, immune checkpoint inhibitors, microsatellite instability, Lynch syndrome, tumor immunology
- MeSH terms
- Antineoplastic Agents, Female, Humans, Male, Neoplasm Metastasis, DNA Mismatch Repair, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.